Rimonyx Pharmaceuticals Ltd.
Rimonyx Pharmaceuticals Ltd. (Rimonyx) is a start-up stage bio-pharmaceutical company, engaged in discovery and development of innovative anti-inflammatory therapeutics. The company makes use of its Glycosaminoglycans (SMIG) platform in identifying the new class of drugs, where the SMIG platform is based on analysis of clinically-proven drugs and involves rational drug design. Many lead compounds against pro-inflammatory chemokines and cytokines are being discovered by Rimonyx to meet the growing need of the market. Its platform is also used to develop vaccines for cancer, amyloid disorders, and viral diseases. The company is actively seeking corporate partnerships to develop and commercialize its drug discovery programs. Rimonyx is headquartered in Ness-Ziona, Israel.